The FDA granted an emergency use authorization for plasma in the treatment of COVID-19 patients. Leaders from the World Health Organization remain skeptical, however, because studies have produced inconclusive results. (Reuters)
The National Institutes of Health will study another Gilead coronavirus drug. The compound is similar to remdesivir. It has not yet been tested in humans. (STAT)
The first coronavirus reinfection has been documented in Hong Kong. The individual, first infected with COVID-19 in March, has contracted the virus again more than four months later. The case raises questions about how long antibodies last for the virus. (STAT)
U.S. COVID-19 cases and deaths dropped last week. This is the fifth week in a row that new cases have decreased. More than 6,700 deaths were recorded, down 9% from the previous seven days. (Reuters)
Novavax to begin enrollment for its phase 2 coronavirus vaccine trial. This phase will include participants between 60 and 84 years. Earlier studies showed the vaccine produced high levels of virus-fighting antibodies. (Reuters)
